IQVIA, Illumina, Mayo Clinic and Arc Institute Harness NVIDIA AI and Accelerated Computing to Transform $10 Trillion ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional cancer ...

Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...

Deal values Aragen at approximately $1.4 billion, with Quadria acquiring a minority stake through a combination of fresh ...

A tunnel along the border wall in Texas, going from Mexico into the U.S. and believed to have been used by smugglers, was ...

The deal values privately held Truveta at more than $1 billion, it said. Biotechnology company Regeneron pledged to put in ...

Wockhardt, founded in 1967, now has six novel formulations in the pipeline, with a second drug Zaynich also expected to ...

ATR-Targeted Molecules Designed for CNS Penetration Set the Stage for Next-Generation Treatments VANCOUVER, British Columbia, (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ( TSX-V: RKV ), a ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...

Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the ...

Telix Pharmaceuticals Limited today announces it has entered into an asset purchase agreement with antibody engineering ...